Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2007-09-04
2007-09-04
Yaen, Christopher (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
Reexamination Certificate
active
09875823
ABSTRACT:
This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.
REFERENCES:
patent: 4847201 (1989-07-01), Kaswasaki et al.
patent: 5109113 (1992-04-01), Caras et al.
patent: 5290551 (1994-03-01), Berd
patent: 5382427 (1995-01-01), Plunkett et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5637483 (1997-06-01), Dranoff et al.
patent: 5681562 (1997-10-01), Sobol et al.
patent: 5759535 (1998-06-01), Cohen et al.
patent: 5866115 (1999-02-01), Kanz et al.
patent: 5891432 (1999-04-01), Hoo
patent: 6033674 (2000-03-01), Jaffee et al.
patent: 6051218 (2000-04-01), McBride
patent: 6277368 (2001-08-01), Hiserodt et al.
patent: 2001/0038841 (2001-11-01), Hiserodt et al.
patent: 441425 (1995-10-01), None
patent: 538952 (1993-04-01), None
patent: 569678 (1993-11-01), None
patent: WO 92/05262 (1992-02-01), None
patent: WO 92/05805 (1992-04-01), None
patent: WO 93/07906 (1993-04-01), None
patent: WO 95/16775 (1995-06-01), None
patent: WO 95/23216 (1995-08-01), None
patent: WO 95/31107 (1995-11-01), None
patent: WO 96/05866 (1996-02-01), None
patent: WO 96/07433 (1996-03-01), None
patent: WO 96/29394 (1996-09-01), None
patent: WO 97/20938 (1997-06-01), None
patent: WO 97/28251 (1997-08-01), None
patent: WO 98/06746 (1998-02-01), None
patent: WO 98/16246 (1998-04-01), None
patent: WO 98/48012 (1998-10-01), None
patent: WO 99/06544 (1999-02-01), None
Chen et al (Blood 2002; 100:1373-80).
Jadus et al (Blood Jun. 15, 1996;87(12):5232-41).
Kimura et al (Exp Hematol Feb.1996;24(2):360-3).
Dermer (Bio/Technology Mar. 12, 1994; p. 320).
Weiss (Washington Post May 6, 1998; A3).
Kimura et al (Exp Hematol Feb. 1996;24(2):360-3).
Dick Je et al (Cancer Surv. 1992;15:161-81.).
Cosman et al (Behring. Inst. Mitt. Aug. 1988; (83):15-26.
Abe et al., “Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432”Cancer Immunol. Immunother. (1995) 41:82-86.
Allione et al. “Immunizing and curative potential of replicating and nonreplacing murine mammary adenocarcinoma cells engineered with interleukin (IL-)2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor , granulocyte-macrophage colony-stimulating factor, and -interferon gene or admixed with conventonal adjuvants”Cancer Res. (1994) 54:6022-6026.
Asher et al. “Murine tumor cells transduced with the gene for tumor necrosis factor-”J. Immunology. (1991) 146:3227-3234.
Berd et al. “Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patents”J. Clin. Oncol. (1990) 8:1858-1867.
Blankenstein et al. “Tumor suppression after tumor cell-targeted necrosis factor gene transfer”J. Exp. Med. (1991) 173:1047-1052.
Borden, Ernst C. and Sondel, Paul M., “Lympokines and Cytokines as Cancer”. 65:800-814, (1990).
Borrelli, Emiliana, et al. “Targeting of an Inducible Toxic Phenotype in Animal Cells.”Proc. Natl. Acad. Sci USA. 85:7572-7576 (1988).
Brown, D. “Gene Therapy ‘Oversold’ by Researchers, Journalists, ” The Washington Post, A22, Dec. 8, 1995.
Bubenik, J. et al., “Immunotherapy of Cancer using Local Administration of Lymphoid Cells Transformed by IL-2c DNA and Constitutively Producing IL-2”.Immunology Letters23:287-292 (1998/1990).
Bubenik, J. et al., “Local Administration of Cells Containing an Inserted IL-2 Gene and Producing U2 Inhibits Growth of Human Tumors in Nu/Nu Mice.”Immunology Letters. 19:279-282 (1988).
Coghlan, A. “Gene dream fades away, ”New Scientist, vol. 145:14-15, Nov. 25, 1995.
Colombo, “Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?”Cancer Immunol. Immunother. (1995) 41:265-270.
Colombo, et al. “Granulocyte Colony-stimulating a Factor Gene Transfer Suppresses Tumorigenicity of a Murine Adenocarcinoma in Vivo.”J. Exp. Med. 173:889-897 (1991).
Dillman et al., “Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy”J. Immunother. (1993) 14:65-69.
Dranoff et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity”Proc. Natl. Acad. Sci. USA(1993) 90:3539-3543.
Fakhrai et al., “Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity”Human Gene Therapy(1995) 6:591-601.
Fearon et al., “Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response”Cell(1990) 60:397-403.
Gabrilove, Janice 1.and Jakubowski, Ann “Hematopoetic Growth Factors: Biology and Clinical Application”.J of the National Cancer Inst. Monographs. 10:73-77 (1990).
Gandolfi, L. et al., “Intratumoral Echo-guided Injection of Interleukin-2 and Lymphokine Activated Killer Cells in Hepatorcellular Carcinom.”Hepato-gastroenterol 36:352-356.
Gansbacher Bernd, et al., “Retroviral Vector-Mediated. Tau. Interferon Gene Transfer into Tumor Cells Generates Potent and Antitumor Immunity.”Cancer Research 50;7820-7825 (1990).
Gansbacher, Bernd et al., “Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity”,J. Exp. Med, 90:1237-1224 (1990).
Gansbacher, et al. “Retroviral Vector-Mediated Cytokine-Gene Transfer into Tumor Cells.”Cancer Investigation, vol. 11(3):345-354, Mar. 1993.
Golumbek et al., “Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design”Cancer Research(1993) 53:5841-5844.
Golumbek et al., “Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines”J. Immunother. (1992) 12:224-230.
Golumbek et al., “Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4”Science(1991) 254:713-716.
Graf et al. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor.J. Immunol. 163:5544, 1999.
Graf et al., “Adenovirus-mediated gene transfer into experimental rat gliomas”Soc. Neuroscience(1995) 21:2135 (Abstract 838.5).
Graf et al., “T9 rat glioma cells secreting human TNF immunize Fischer rats against untransfected T9 and L9 gliomas”Proc. Amer. Assoc. Cancer Res. (1994) 35:500 (Abstract 2978).
Hoover, H.C. Jr. et al., “Delayed Cutaneous Hypersensitivity to Autologous Tumor Cells in Colorectal Cancer Patients Immunized With the Autologous Tumor Cell”:Bacillus-calmetteGuerin Vaccine,Cancer Res. 44:1671-1676 (1984).
Jadus et al. Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony stimulating factor.Blood87:5232, 1996.
Jaffee et
Graf Martin R.
Granger Gale A.
Hiserodt John C.
Francis Carol L.
The Regents of the University of California
Yaen Christopher
LandOfFree
Cancer immunotherapy using autologous tumor cells combined... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer immunotherapy using autologous tumor cells combined..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy using autologous tumor cells combined... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751665